Translating microbiome research into personalized schizophrenia care by implementing multi-omics and artificial intelligence

Abstract

Schizophrenia is widely recognized as a multifactorial disorder involving interactions among the central nervous system, immune system, metabolism, and gut microbiome. Mardon et al. highlighted the potential importance of the gut-brain axis in schizophrenia. Building on this perspective, this commentary examines the next phase of schizophrenia research: translating biological discoveries into clinically meaningful applications. The discussion focuses on the potential role of integrated biological biomarkers, multi-omics, and artificial intelligence (AI) in precision psychiatry, while also examining the barriers that currently limit clinical implementation. By combining biological data with computational analysis, translational research may ultimately support more individualized approaches to the diagnosis and management of schizophrenia.